Kaleido Biosciences Inc (KLDO)
0.00
USD |
OTCM |
Nov 13, 16:00
Price Chart
Key Stats
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.0% |
Profile
| Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome. |
| URL | http://www.kaleido.com |
| Investor Relations URL | https://investors.kaleido.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Dec. 31, 2024 (est.) |
| Last Earnings Release | Nov. 01, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome. |
| URL | http://www.kaleido.com |
| Investor Relations URL | https://investors.kaleido.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Dec. 31, 2024 (est.) |
| Last Earnings Release | Nov. 01, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |